Patents Examined by Jeffrey E. Russel
-
Patent number: 11993652Abstract: The present disclosure relates to tagged chimeric effector molecules and receptor molecules thereof for genetically engineering a host cell, wherein the recombinant host cell can be identified, isolated, sorted, induced to proliferate, tracked or eliminated. For example, a T cell may be recombinantly modified for use in adoptive immunotherapy.Type: GrantFiled: May 24, 2021Date of Patent: May 28, 2024Assignee: Fred Hutchinson Cancer CenterInventors: Stanley R. Riddell, Lingfeng Liu
-
Patent number: 11981704Abstract: Synthetic methods are described herein operable to efficiently produce a wide variety of molecular species through conjugate additions via decarboxylative mechanisms. For example, methods of functionalization of peptide residues are described, including selective functionalization of peptide C-terminal residues. In one aspect, a method of peptide functionalization comprises providing a reaction mixture including a Michael acceptor and a peptide and coupling the Michael acceptor with the peptide via a mechanism including decarboxylation of a peptide reside.Type: GrantFiled: September 8, 2021Date of Patent: May 14, 2024Assignee: THE TRUSTEES OF PRINCETON UNIVERSITYInventors: David MacMillan, Daniel Novoa, Stefan McCarver
-
Patent number: 11975050Abstract: Disclosed are peptide-fatty acid conjugates, pharmaceutical compositions containing them, and methods of their medical use in the treatment of, e.g., a disease or condition associated with the PTHR1 signaling overactivity (e.g., hypercalcemia, hypophosphatemia, hyperparathyroidism, or Jansen's chondrodysplasia) or deficiency (e.g., hypoparathyroidism, hyperphosphatemia, osteoporosis, fracture repair, osteomalacia, arthritis, or thrombocytopenia).Type: GrantFiled: March 15, 2019Date of Patent: May 7, 2024Assignee: The General Hospital CorporationInventors: Thomas J. Gardella, Ashok Khatri, Hiroshi Noda
-
Patent number: 11975053Abstract: Disclosed is a wound treatment that includes collagen and a gelatin-reducing agent. Also disclosed is a wound dressing including a substrate, collagen, and a gelatin-reducing agent. The collagen and gelatin-reducing agent may be present in any suitable a weight ratio relative to one another, such as a weight ratio of about 0.25:1 to about 4:1 with respect to one another. Also disclosed is a method for promoting wound healing including administering collagen and a gelatin-reducing agent to a wound in need of treatment.Type: GrantFiled: July 27, 2022Date of Patent: May 7, 2024Assignee: Medline Industries, LPInventors: Debashish Chakravarthy, Brian Mattorano, Anthony Frei
-
Patent number: 11975047Abstract: A method of storing and warming a sterile corticotropin composition by storing the sterile corticotropin composition in a multiple-dose vial comprising 80 USP units/mL of the sterile corticotropin composition, wherein the vial comprises a rubber stopper coated with cross-linked silicones, at a temperature of 2° to 8° C.; and warming the vial to a temperature of 18° to 26° C., wherein the corticotropin comprises amino acids 1-39 of SEQ ID NO: 1, or wherein the sterile corticotropin composition has not more than 0.05 USP Vasopressin Units/USP Corticotropin Units.Type: GrantFiled: October 27, 2023Date of Patent: May 7, 2024Assignee: ANI Pharmaceuticals, Inc.Inventors: Edward M. DeSimone, III, Weijun Cheng, Zachary Holcomb
-
Patent number: 11976094Abstract: A method for preparing peptides is disclosed, the method comprising a step of forming a peptide bond wherein the carboxyl group of a first amino acid or first peptide is activated and an amino group of the first activated amino acid or first peptide is protected by a protecting group having a water-solubility enhancing group and the activated carboxyl group of the first amino acid or first peptide is reacted with an amino group of a second amino acid or second peptide wherein said carboxyl group of the first amino acid or first peptide is activated in the absence of the second amino acid or second peptide. Peptides comprising a protecting group having a water-solubility enhancing group being bound to the amino group and an activated or free carboxyl group are also disclosed.Type: GrantFiled: March 28, 2022Date of Patent: May 7, 2024Assignee: Sulfotools GmbHInventor: Sascha Knauer
-
Patent number: 11944663Abstract: The present patent application provides methods for treating patients having angiogenic eye disorder by administering a VEGF antagonist, particularly an VEGF antagonist comprising the amino acid sequence of SEQ ID NO:1 in one or more treatment phases.Type: GrantFiled: June 18, 2021Date of Patent: April 2, 2024Assignee: Chengdu Kanghong Biotechnologies Co. Ltd.Inventor: Zunhong Ke
-
Patent number: 11939362Abstract: A light-inducible intracellular protein aggregation system is described herein, which provides invaluable tools to study the role of protein aggregates in proteinopathies and to screen for novel therapeutic compounds. The system generally comprises a cell expressing an alpha-synuclein polypeptide or another proteopathic polypeptide that self-aggregates under pathogenic conditions, operably linked to a photoactivatable polypeptide. Illumination of the photoactivatable polypeptide with light having a wavelength sufficient for photoactivation triggers irreversible accumulation of intracellular protein aggregates comprising the alpha-synuclein polypeptide or proteopathic polypeptide. The intracellular protein aggregates can be made to accumulate in real-time during the illumination, thereby enabling spatiotemporal control of protein aggregation.Type: GrantFiled: July 3, 2019Date of Patent: March 26, 2024Assignee: UNIVERSITÉ LAVALInventor: Abid Oueslati
-
Patent number: 11932676Abstract: Recombinant Klotho proteins, nucleic acids encoding the same, cell lines and cultures expressing the same, and method of manufacturing and administering the same are disclosed. Proteins have at least 80% amino acid sequence identity to a portion of human alpha Klotho and preferably a solubility or half-life-extending feature such as glycosylation and/or fusion protein tag. Treatment protocols include determining Klotho levels in a subject, calculating a dosage of the protein sufficient to raise the Klotho level in the subject to a predetermined level, administering the dosage to the subject, determining a rate of protein decline in the subject following administration of the protein, calculating a time and/or amount of a subsequent dosage of the protein, and/or administering the subsequent dosage to the subject. Proteins and related treatments for addressing aging-associated and other conditions are disclosed.Type: GrantFiled: November 22, 2017Date of Patent: March 19, 2024Assignee: KLOTHO THERAPEUTICS, INC.Inventors: Joseph F. Tarsio, Dinesh Raturi, James R. Plante
-
Patent number: 11918628Abstract: The present invention relates to a controlled-release parathyroid hormone (PTH) compound in which PTH(1-34) is reversibly conjugated to a branched polyethylene glycol. The invention further relates to a pharmaceutical composition of the compound. The compound or pharmaceutical composition is useful for treatment, control, delay or prevention of a condition that can be treated, controlled, delayed or prevented with PTH.Type: GrantFiled: July 19, 2023Date of Patent: March 5, 2024Assignee: ASCENDIS PHARMA BONE DISEASES A/SInventors: Kennett Sprogøe, Felix Cleemann, Guillaume Maitro, Mathias Krusch, Thomas Wegge, Joachim Zettler
-
Patent number: 11911438Abstract: The present invention provides lyophilized formulations of active agents, particularly of TAT-NR2B9c, as chloride salts. TAT-NR2B9c has shown promise for treating stroke, aneurysm, subarachnoid hemorrhage and other neurological or neurotraumatic conditions. The chloride salt of TAT-NR2B9c shows improved stability compared with the acetate salt form of prior formulations. Formulations of the chloride salt of TAT-NR2B9c are stable at ambient temperature thus facilitating maintenance of supplies of such a formulation in ambulances for administration at the scene of illness or accident or in transit to a hospital.Type: GrantFiled: December 8, 2021Date of Patent: February 27, 2024Assignee: NoNO Inc.Inventor: Jonathan David Garman
-
Patent number: 11913028Abstract: The present invention relates to artificial transcription factors (ATFs) that alter gene expression, including inducing pluripotency in cells or promoting the conversion of cells to specific cell fates. In particular, provided herein is a zinc-finger based ATF library that can be screened in cells by looking for expression of a specific gene (e.g., reporter expression), monitoring for cell surface markers or morphology, or via functional assays.Type: GrantFiled: June 16, 2021Date of Patent: February 27, 2024Assignee: Wisconsin Alumni Research FoundationInventors: Asuka Eguchi, Aseem Z. Ansari
-
Patent number: 11911388Abstract: The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in patients with insufficient glycemic control despite a therapy with an oral and/or a non-oral antidiabetic drug.Type: GrantFiled: February 11, 2021Date of Patent: February 27, 2024Assignee: Boehringer Ingelheim International GmbHInventors: Eva Ulrike Graefe-Mody, Thomas Klein, Michael Mark, Hans-Juergen Woerle
-
Patent number: 11896724Abstract: A wound dressing includes: a structural material formed into a dressing; at least one immunomodulatory agent associated with the dressing; and a growth factor associated with the dressing. A wound dressing kit includes: a structural material formed into a wound dressing; an immunomodulatory agent; and a growth factor composition, wherein the structural material contains the immunomodulatory agent and/or the immunomodulatory agent in a separate composition. A method of treating a wound in a tissue includes: applying an immunomodulatory agent to the wound; applying a wound dressing to the wound; and allowing the wound to heal with the immunomodulatory agent and wound dressing. The application of a growth factor can be before, during and/or after applying the wound dressing to the wound.Type: GrantFiled: October 7, 2020Date of Patent: February 13, 2024Assignee: Arizona Board of Regents on behalf of Arizona State UniversityInventors: Kaushal Rege, Deepanjan Ghosh
-
Patent number: 11890317Abstract: A new use of a cyclo histidine-proline (Cyclo His-Pro, CHP) is disclosed. A composition including cyclo histidine-proline (CHP) as an active ingredient has an excellent protective effect to protect kidney and liver cells from damage and/or toxicity induced by various causes. The composition is useful and effective in protecting kidney and/or liver cells/tissues and in treating a subject with kidney and/or liver diseases and/or damages.Type: GrantFiled: July 1, 2022Date of Patent: February 6, 2024Assignee: NovMetaPharma Co., Ltd.Inventors: Hoe-Yune Jung, Heon-Jong Lee, Jong-Su Jeon, Yon-Su Kim, Seung-Hee Yang, Yong-Chul Kim, Jong-Joo Moon, Hwan-Soo Yoo, Kyeong-Mi Choi
-
Patent number: 11890326Abstract: The present invention relates to a controlled-release parathyroid hormone (PTH) compound in which PTH(1-34) is reversibly conjugated to a branched polyethylene glycol. The invention further relates to a pharmaceutical composition of the compound. The compound or pharmaceutical composition is useful for treatment, control, delay or prevention of a condition that can be treated, controlled, delayed or prevented with PTH.Type: GrantFiled: December 8, 2022Date of Patent: February 6, 2024Assignee: ASCENDIS PHARMA BONE DISEASES A/SInventors: Kennett Sprogøe, Felix Cleemann, Guillaume Maitro, Mathias Krusch, Thomas Wegge, Joachim Zettler
-
Patent number: 11883496Abstract: A physically stable compositions in the form of an injectable aqueous solution with a pH from 6.0 to 8.0, include a basal insulin whose isoelectric point (pI) is from 5.8 to 8.5, and a co-polyamino acid bearing carboxylate charges and at least one hydrophobic radical.Type: GrantFiled: June 15, 2020Date of Patent: January 30, 2024Assignee: ADOCIAInventors: You-Ping Chan, Alexandre Geissler, Romain Noel, Richard Charvet, Nicolas Laurent
-
Patent number: 11879018Abstract: Circular handed alpha-helical repeat proteins are described. The repeat proteins have a number of uses as scaffolds for geometrically precise, arrayed presentation of cell-signaling or immune-related protein and peptide epitopes, as well as numerous other therapeutic, diagnostic, and nanotechnological uses.Type: GrantFiled: June 28, 2021Date of Patent: January 23, 2024Assignee: Fred Hutchinson Cancer CenterInventors: Philip Bradley, Barry L. Stoddard
-
Patent number: 11850313Abstract: A tissue oxygenation composition comprising (a) an oxygenated solution or a solution containing an oxygen carrier and (b) hydrogen sulfide (H2S). The disclosure also relates to methods of preserving, reperfusing and/or transfusing tissue with a tissue oxygenation composition according to the present disclosure.Type: GrantFiled: December 18, 2020Date of Patent: December 26, 2023Assignee: The London Health Sciences Centre Research Inc.Inventors: Alp Sener, Smriti Juriasingani
-
Patent number: 11840582Abstract: The present disclosure relates to a method of synthesizing cyclosporine derivatives. The method includes: providing a precursor fluid of the cyclosporine derivative, an alkaline fluid and a ClCH2OCOCl solution; premixing the precursor fluid and the alkaline fluid to obtain a premixed solution; feeding the premixed solution into a first reaction chamber, reacting to prepare a first reaction liquid; feeding the first reaction liquid into a second reaction chamber, reacting the first reaction liquid with a CO2 fluid to prepare a second reaction liquid; and reacting the second reaction liquid with the ClCH2OCOCl solution.Type: GrantFiled: July 12, 2021Date of Patent: December 12, 2023Assignee: Peking University Shenzhen Graduate SchoolInventors: Zhen Yang, Qingzhou Zhang, Fengxia Li, Chongguo Jiang, Jianxian Gong, Jun Huang, Weibin Zhang